The estimated Net Worth of Mark H Skolnick is at least $8.63 Milione dollars as of 4 November 2009. Mark Skolnick owns over 192,000 units of Myriad Genetics stock worth over $893,520 and over the last 22 years Mark sold MYGN stock worth over $7,736,665.
Sign up
Mark Skolnick MYGN stock SEC Form 4 insiders trading
Mark has made over 23 trades of the Myriad Genetics stock since 2005, according to the Form 4 filled with the SEC. Most recently Mark sold 192,000 units of MYGN stock worth $4,884,480 on 4 November 2009.
The largest trade Mark's ever made was selling 192,000 units of Myriad Genetics stock on 4 November 2009 worth over $4,884,480. On average, Mark trades about 12,439 units every 40 days since 2003. As of 4 November 2009 Mark still owns at least 34,000 units of Myriad Genetics stock.
You can see the complete history of Mark Skolnick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Mark Skolnick's mailing address?
Mark's mailing address filed with the SEC is , , , , .
Insiders trading at Myriad Genetics
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum e Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
What does Myriad Genetics do?
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
What does Myriad Genetics's logo look like?
Complete history of Mark Skolnick stock trades at Myriad Genetics
Myriad Genetics executives and stock owners
Myriad Genetics executives and other stock owners filed with the SEC include:
-
R. Bryan Riggsbee,
Chief Financial Officer, Executive Vice President, Treasurer -
Bernard Tobin,
President - Myriad Autoimmune -
Jerry Lanchbury,
Chief Scientific Officer -
Paul J. Diaz,
CEO, Pres & Director -
R. Bryan Riggsbee,
Exec. VP, CFO & Treasurer -
Dr. Jerry S. Lanchbury Ph.D.,
Chief Scientific Officer -
Dr. Jerry S. Lanchbury,
Chief Scientific Officer -
Mark S. Verratti,
Pres of Myriad Neuroscience & Autoimmune -
Nicole Lambert,
Chief Operating Officer -
John Henderson,
Independent Director -
S. Louise Phanstiel,
Independent Chairman of the Board -
Dennis Langer,
Independent Director -
Heiner Dreismann,
Independent Director -
Lawrence Best,
Independent Director -
Walter Gilbert,
Independent Vice Chairman of the Board -
Daniel Spiegelman,
Independent Director -
Daniel Skovronsky,
Independent Director -
Colleen Reitan,
Independent Director -
Lee Newcomer,
Independent Director -
Rashmi Kumar,
Independent Director -
Mark Pollack,
Chief Medical Officer -
Gary King,
Executive Vice President - International Operations -
Benjamin Jackson,
Executive Vice President, General Counsel, Secretary -
Mark Verratti,
President - Myriad Neuroscience -
Ralph McDade,
President - Myriad RBM -
Nicole Lambert,
President - Myriad Oncology -
Paul Diaz,
President, Chief Executive Officer, Director -
Pamela Wong,
Chief Legal Officer -
Nathan Smith,
Sr. VP of Investor Relations & Treasury -
Dr. Kevin Richard Haas,
Chief Technology Officer -
Paul Chip Parkinson,
Exec. VP of Reimbursement Strategy -
Jayne Baird Hart,
Exec. VP of HR -
Dr. Clivetty Martinez,
Chief Compliance Officer -
Benjamin Jackson,
Exec. VP, Gen. Counsel & Sec. -
Scott Gleason,
Sr. VP of Investor Relations -
Kevin Richard Haas,
Chief Technology Officer -
Alexander Ford,
Chief Operating Officer -
Kevin Richard Haas,
Chief Technology Officer -
Heinrich Dreismann,
Director -
Richard Wenstrup,
Chief Medical Officer -
Virginia Drosos,
President Assurex Health -
Richard M Marsh,
V.P., General Counsel -
Mark Christopher Capone,
President & C.E.O. -
Samraat S. Raha,
Chief Operating Officer -
Pamela Wong,
Chief Legal Officer -
Walter Lloyd Sanders,
President Myriad Oncology -
Linda S Wilson,
Director -
Mark H Skolnick,
Chief Scientific Officer -
Gerald P. Belle,
Director -
Adrian N Hobden,
President -
W Wayne Laslie,
Chief Operating Officer, MPI -
Robert S Attiyeh,
Director -
Dale A Stringfellow,
Director -
Arthur Hull Jr Hayes,
Director -
Arthur H Jr Hayes,
Director -
William A Iii Hockett,
Vice President -
Gregory C Critchfield,
President -
Jay M Moyes,
Chief Financial Officer -
S George Simon,
Vice President -
Robert Gardner Harrison,
Chief Information Officer -
Ronald S. Rogers,
Exec VP Corp Communications -
James S Evans,
V.P. Finance -
T Craig Benson,
President, Myriad RBM -
Paul Bisaro,
Director -
Eric Santa,
Former Chief Growth Officer -
Paul Parkinson,
Fmr EVP Strategy & Innovation -
Margaret Ancona,
SVP, Chief of Staff -
Dale Muzzey,
Chief Scientific Officer -
Natalie Munk,
Chief Accounting Officer -
Heinrich Dreismann,
Director -
Jayne B. Hart,
See Remarks -
Shereen Solaiman,
Chief People Officer -
Scott J. Leffler,
Chief Financial Officer -
Jennifer Lynne Fox,
Chief Legal Officer